Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 10/20 | 0.51 |
| ▸ | FEN1 | P39748 | 10/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | COMT | P21964 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 3/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2000949 | 1.00 | ALOX5AP (0.51) | ALOX5APFEN1L3MBTL1COMTCNR1 | |
| SCHEMBL2000952 | 1.00 | ALOX5AP (0.51) | ALOX5APFEN1L3MBTL1COMTCNR1 | |
| SCHEMBL2001133 | 0.88 | ALOX5AP (0.45) | ALOX5APFEN1CNR1CNR2BRD4 | |
| SCHEMBL1998886 | 0.88 | ALOX5AP (0.45) | ALOX5APFEN1COMTCNR1BRD4 | |
| SCHEMBL2003081 | 0.88 | ALOX5AP (0.45) | ALOX5APFEN1COMTCNR1BRD4 | |
| SCHEMBL1998882 | 0.88 | ALOX5AP (0.45) | ALOX5APFEN1COMTCNR1BRD4 | |
| SCHEMBL2001131 | 0.88 | ALOX5AP (0.45) | ALOX5APFEN1CNR1CNR2BRD4 | |
| SCHEMBL2004250 | 0.88 | ALOX5AP (0.45) | ALOX5APFEN1CNR1CNR2BRD4 | |
| SCHEMBL2008831 | 0.84 | ALOX5AP (0.49) | ALOX5APFEN1COMTJAK2JAK1 | |
| SCHEMBL2007211 | 0.84 | ALOX5AP (0.49) | ALOX5APFEN1COMTJAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964613-B2 | (S)-3-amino-1-(4-bromo-5-isoquinolinesulfonyl)pyrrolidine; inhibits phosphorylation of myosin regulatory light chain; for spinal canal stenosis, spinal cord injury, rheumatoid arthritis, multiple sclerosis; Rho kinase inhibitors | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-06-21 | — | — | US | claimed |
| EP-1932841-B1 | SULFONAMIDE COMPOUND | ASAHI KASEI PHARMA CORP (JP) | 2014-01-01 | — | — | EP | disclosed |
| US-8415372-B2 | Sulfonamide compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2013-04-09 | — | — | US | disclosed |
| US-7964613-B2 | (S)-3-amino-1-(4-bromo-5-isoquinolinesulfonyl)pyrrolidine; inhibits phosphorylation of myosin regulatory light chain; for spinal canal stenosis, spinal cord injury, rheumatoid arthritis, multiple sclerosis; Rho kinase inhibitors | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-06-21 | — | — | US | disclosed |
| US-20100093789-A1 | SULFONAMIDE COMPOUND | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-04-15 | — | — | US | disclosed |
| EP-2130828-A1 | SULFONAMIDE DERIVATIVE | Asahi Kasei Pharma Corporation (JP) | 2009-12-09 | — | — | EP | disclosed |
| US-7618984-B2 | Sulfonamide compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-11-17 | — | — | US | disclosed |
| US-20090048223-A1 | Sulfonamide compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-02-19 | — | — | US | disclosed |
| EP-1932841-A1 | SULFONAMIDE COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2008-06-18 | — | — | EP | disclosed |
| US-20070179127-A1 | Sulfonamide compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093789-A1 | SULFONAMIDE COMPOUND | AKT1, ROCK1, ROCK2 | ALOX5AP 4150/4885FEN1 4212/4885L3MBTL1 2322/4885 |
| US-20070179127-A1 | Sulfonamide compound | MYLK, MYLK2, MYLK3 | ALOX5AP 4520/4885FEN1 4586/4885L3MBTL1 1490/4885 |
| US-20090048223-A1 | Sulfonamide compound | ALK, AKT1, ARAF | ALOX5AP 3609/4885FEN1 4520/4885L3MBTL1 2449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.